Patient and tumour demographics of all patients with HCC assessed for liver transplantation January 2015–January 2020
| Demographics | All patients n=263 | Listed n=168 | Not listed n=95 | P value |
| Male | 210 (80%) | 136 (81%) | 74 (78%) | 0.56 |
| Ethnicity | ||||
| Asian | 19 (7%) | 11 (7%) | 8 (8%) | 0.77 |
| Black | 5 (2%) | 3 (2%) | 2 (2%) | >0.99 |
| Chinese | 2 (1%) | 2 (1%) | 0 | 0.54 |
| Mixed | 4 (2%) | 4 (2%) | 0 | 0.3 |
| Not specified | 56 (21%) | 23 (14%) | 33 (35%) | <0.05 |
| Other | 3 (1%) | 2 (1%) | 1 (1%) | >0.99 |
| White | 174 (66%) | 123 (73%) | 51 (54%) | <0.05 |
| Age (years) (IQR) | 62 (56–66) | 61 (55–65) | 64 (58–67) | <0.05 |
| Cirrhosis present | 250 (95%) | 156 (93%) | 94 (99%) | |
| Aetiology of cirrhosis | ||||
| ArLD | 64 (24%) | 35 (21%) | 29 (31%) | 0.32 |
| MASLD | 55 (21%) | 32 (19%) | 23 (24%) | 0.12 |
| Viral | 64 (24%) | 46 (27%) | 18 (19%) | <0.05 |
| Mixed pathology | 51 (19%) | 32(19%) | 19 (20%) | <0.05 |
| HH | 7 (3%) | 6 (4%) | 1 (1%) | <0.05 |
| PBC | 9 (3%) | 7 (4%) | 2 (2%) | 0.08 |
| Other | 13 (5%) | 10 (6%) | 3 (3%) | <0.05 |
| Tumour size (cm) (SD) | 2.9 (1.15) | 2.9 (1) | 3.1 (1.26) | 0.36 |
| Number of tumours (SD) | 1.5 (0.99) | 1 (0.9) | 2 (1.1) | <0.05 |
| AFP (kU/L) (IQR) | 6 (3–19) | 6 (3–16) | 6 (4–25) | 0.51 |
| UKELD (IQR) | 48 (46–51) | 48 (46–51) | 49 (47–52) | 0.07 |
| Diabetes | 110 (42%) | 58 (34%) | 52 (55%) | <0.05 |
| IHD | 17 (6%) | 7 (4%) | 10 (11%) | <0.05 |
AFP, alpha foetoprotein; ArLD, alcohol-related liver disease; HCC, hepatocellular carcinoma; HH, hereditary haemochromatosis; IHD, ischaemic heart disease; MASLD, metabolic-associated steatotic liver disease; PBC, primary biliary cholangitis; UKELD, United Kingdom Model for End-Stage Liver Disease.